

# Call for experts

## for a EUPHA Working Group on Access to Medicines

### Background

All citizens in Europe and beyond should have access to essential medicines that are affordable and of high quality. However, the current laws, rules and processes that regulate access of medicinal products – including vaccines – to the market and determine availability and distribution of these products for patients/citizens, do not always have the desired effects. We see problems such as (extremely) high prices, stock shortages, unequal/unfair distribution - as we have seen e.g., during the COVID-19 pandemic -, market access for medicines with very little added value, and persistently inadequately addressed unmet societal needs (e.g., lack of investment in new antimicrobials and in medicines for neglected tropical diseases). Access to medicines as an element of Universal Health Coverage therefore is an important topic for EUPHA. Currently, several important developments are ongoing that will impact on access to medicines in Europe, most notably the revision of the EU pharmaceutical legislation, the establishment of the Access to Novel Medicines Platform (NMP) by WHO-Euro as an outcome of the Oslo Medicines Initiative, and the development of a global Pandemic Treaty. This means that there is a clear momentum to bring in the public health perspective and make sure that an evidence-based and equitable population health lens is applied in these policy processes. To help EUPHA in their advocacy for this, EUPHA is calling for experts for an advisory working group on access to medicines.

### What are we looking for? Required profile:

- Demonstrable expertise in one or more of the following themes:
  - Costing models / R&D processes and costs for new medicines including vaccines
  - Market access regulations and approaches for new medicines including vaccines (particularly in an EU context)
  - Procurement of medicines including vaccines and stock piling (particularly in an EU context)
  - (EU and global) market dynamics for medicines including vaccines
  - IP and technology sharing/knowledge transfer
  - EU Pharmaceutical Legislation
  - AMR / access to antimicrobials and diagnostics
  - Equitable distribution of medicines including vaccines / inequities in access to medicines including vaccines
- You preferably are a EUPHA member or otherwise you are active in one of the EUPHA sections and familiar with EUPHA as an organization.
- You are committed to EUPHA's vision, mission and values.

### Expected contribution

- You will be requested on an ad hoc basis to provide input for e.g., statements or consultations. Depending on the situation, online meetings may be organized by the EUPHA

office for discussions with the entire working group. Expected time investment: 4-6 hours per month.

- You may be asked to represent EUPHA at a relevant (online or in-person) meeting or event.
- The working group will be established for the duration of two years initially. After that, the EUPHA Executive Council will evaluate whether the working group will be continued and if so, in what form.

**Please note:**

- This is a voluntary position, meaning that you will receive no remuneration for the time spent in support of the working group.
- When EUPHA office asks you to represent EUPHA in an in-person meeting, EUPHA will cover for your travel and accommodation when this is not taken care of by the inviting organization.
- Working group members will be listed on the EUPHA website. A certificate acknowledging working group membership can be provided by EUPHA office on request.
- We are looking for 3-5 experts for this working group. The EUPHA Executive Council will assess the applications and decide on the nominations.

**Are you interested in joining this working group?**

We'd love to hear from you! Please send your CV and a short motivation letter to [office@eupha.org](mailto:office@eupha.org) before Friday 16 June CoB.

If you have any questions related to this call for experts, you can contact the EUPHA office at [office@eupha.org](mailto:office@eupha.org).